Biologics Safety Testing Is Becoming More Important as Therapeutic Complexity Increases
The market is estimated to increase from approximately USD 4.9 billion in 2025 to USD 5.3 billion in 2026 and USD 9.4 billion by 2035, representing a CAGR of about 6.6%.
Safety testing can address a broad range of potential risks, including microbial contamination, mycoplasma, endotoxins, bioburden, viral contamination, sterility and residual host-cell proteins or DNA.
For more information on the Biologics Safety Testing Market, visit:
https://www.rootsanalysis.com/....reports/biologics-sa
Gefällt mir
Kommentar
Teilen
